COVID-19 patients in China are still able to apply for reimbursements for Paxlovid, a COVID-19 treatment medicine from Pfizer, as of March 31, an official said on Wednesday.
The COVID-19 treatment molnupiravir is expected to hit the Chinese market on Friday, after passing its first import test on Wednesday, said Liu Yong, president of Sinopharm.
Authorities are in talks with United States drugmaker Pfizer to facilitate domestic manufacturing of Paxlovid, a COVID-19 treatment, to help meet demand in China, a medical expert said on Wednesday.
China has reported all the variants that it has detected to the World Health Organization (WHO) and will continue to shoulder responsibility in tracking new variants.
Chinese authorities are strengthening COVID-19 prevention and control measures in nursing homes and mobilizing the community-level response, officials said on Wednesday.